BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY
Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two...
Prnewswire Debiopharm Debiopharm International Antibody Drug Conjugates Wazoku Platform Drug Targeting Conjugation Method
Source: prnewswire.com